Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral blood-thinning medication over the same extended period. These findings from the API-CAT trial were presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

Investigators at Mass General Brigham have uncovered how resistance to chemotherapies may occur in some cancers. Researchers focused on a pathway that harnesses reactive oxygen species (ROS) to kill cancer cells. The study found that mutations to VPS35, a key player in this pathway, can prevent chemotherapy-induced cell death. These results, published in Nature, could help pinpoint treatment-resistant tumors.

The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, Fellow of the AACR Academy, as the AACR President-Elect for 2025-2026. Flaherty will become President-Elect on Monday, April 28, during the AACR’s Annual Business Meeting of Members at the AACR Annual Meeting 2025 in Chicago, Illinois and will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego, California.

Heart disease remains the leading cause of death in the United States, accounting for one in five deaths. The inability of damaged heart muscle tissue to regenerate makes heart disease difficult to treat, and end-stage heart failure patients have no choice but to join a long list of people waiting for a heart transplant. Researchers from Emory University are working to provide another option for such patients. To do this, the team took their research to a laboratory unlike any on Earth—the International Space Station (ISSInternational Space Station).

 Critical Path Institute^® and Boston Medical Center published results for six biomarkers that could improve the early and accurate detection of kidney injury, leading to both the development of safer medications and better health outcomes for all patients. The results leverage the collaborative expertise and investment of C-Path’s Predictive Safety Testing Consortium’s Nephrotoxicity Working Group, and the Clinical Evaluation and Qualification of Translational Kidney Safety Biomarkers Project, a public-private partnership managed collaboratively by the Foundation for the National Institutes of Health Biomarkers Consortium Kidney Safety Biomarker Project Team.

A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more effective model for predicting how patients with muscle-invasive bladder cancer will respond to chemotherapy. The model harnesses whole-slide tumor imaging data and gene expression analyses in a way that outperforms previous models using a single data type.